{"preliminary_commentary":{"by_channel":{"x_thread":6,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"FOURLIGHT-3","nct_id":"NCT06760637","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fourlight-3-nct06760637. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"FourLight-3","arms":[{"description":"PF-07220060 tablet taken by mouth plus Letrozole tablet taken by mouth","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Investigator's Choice of CDK4/6 inhibitor (tablet/capsule) taken by mouth with letrozole tablet taken by mouth","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2037-12-29","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":1035,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"PF-07220060","otherNames":[],"type":"DRUG"},{"name":"letrozole","otherNames":[],"type":"DRUG"},{"name":"abemaciclib","otherNames":[],"type":"DRUG"},{"name":"palbociclib","otherNames":[],"type":"DRUG"},{"name":"ribociclib","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"Pfizer","official_title":"AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-01-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) by BICR","timeFrame":"From the date of randomization until disease progression or death due to any cause (up to approximately 4 years)"}],"references":[],"start_date":{"date":"2025-01-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","url":"https://clinicaltrials.gov/study/NCT06760637"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fourlight-3-nct06760637"}